Corbus Pharmaceuticals Holdings (CRBP) Total Liabilities (2013 - 2025)

Corbus Pharmaceuticals Holdings' Total Liabilities history runs 13 years deep, the most recent figure standing at $20.7 million for Q4 2025.

• On a quarterly basis, Total Liabilities rose 53.83% year-over-year to $20.7 million in Q4 2025; TTM through Dec 2025 was $20.7 million, a 53.83% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 53.83% from the prior year.
• Total Liabilities grew to $20.7 million in Q4 2025 per CRBP's latest filing, from $17.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $48.6 million in Q1 2021 and bottomed at $12.8 million in Q1 2025.
• The 5-year median for Total Liabilities is $33.0 million (2022), against an average of $29.7 million.
• Across the five-year window, Total Liabilities plunged 61.99% in 2024 and jumped 53.83% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $38.6 million in 2021, then declined by 13.72% to $33.3 million in 2022, then advanced by 5.57% to $35.2 million in 2023, then plunged by 61.76% to $13.5 million in 2024, then jumped by 53.83% to $20.7 million in 2025.
• Per Business Quant, the three latest CRBP Total Liabilities figures stand at $20.7 million (Q4 2025), $17.4 million (Q3 2025), and $14.1 million (Q2 2025).